This Common Joint Supplement May Speed Up Alzheimer’s, Study Finds

Glucosamine is one of the most-used supplements in the United States, sold in every pharmacy and big-box store as a solution for creaking knees and arthritic joints. A new study published in June 2026 found that people who take it while already in cognitive decline were 25% more likely to convert to full Alzheimer’s disease than those who did not. The supplement doesn’t just sit in the joints – it crosses into the brain, and for a brain already in trouble, that matters.

The research, published June 9, 2026 in Nature Metabolism by a team at the University of Florida, upends a decade of reassuring data. Earlier observational studies had suggested glucosamine might even lower dementia risk in cognitively healthy people. The new findings don’t erase those earlier results – they narrow them sharply. The picture that emerges is of a supplement that may behave very differently depending on the state of the brain it enters.

Glucosamine is a sugar molecule sold over the counter as a remedy for joint pain and arthritis. More than 40 million Americans take it each year. Most of them assume it’s a benign supplement, since it comes from natural sources and has been on the market for decades. For people with healthy cognition, that assumption may still hold. For people showing early signs of memory loss, the new data suggests it may not.

What the University of Florida Study Found

Researchers at the University of Florida used artificial intelligence to comb through de-identified health records from 2012 to 2024. They found that 8% of both dementia and mild cognitive impairment patients reported taking glucosamine – 1,896 with diagnosed dementia and 2,750 with mild cognitive impairment. After controlling for age, sex, and demographics, glucosamine use was associated with a 25% higher likelihood of progression from mild cognitive impairment to dementia.

Mild cognitive impairment, often called MCI, is the clinical term for a stage where memory and thinking problems are noticeable but not severe enough to interfere fully with daily life. It can be an early indicator of Alzheimer’s disease or dementia, and identifying those with cognitive issues early could lead to interventions and better outcomes. For patients already at this crossroads, the data from the University of Florida study raises a direct question about what role their supplements may be playing.

Researchers also found that taking glucosamine was associated with a 25% increase in mortality risk among patients already diagnosed with Alzheimer’s disease-related dementias. For the MCI group, there was no comparable increase in death risk, suggesting the impact of glucosamine may be greater in patients with established dementia.

The findings are based on a large analysis of patient health records combined with advanced imaging studies of human brain tissue and mouse models of Alzheimer’s disease. That combination – real-world patient data, human post-mortem brain imaging, and animal model experiments – gives the research more depth than a single-method study would.

The Biology Behind the Risk: Hyperglycosylation and Supplement Alzheimer’s Progression

The mechanism the researchers identified is called hyperglycosylation. Proteins in the body regularly get small sugar structures attached to them – a process called glycosylation – and this is a normal part of how proteins fold, travel within cells, and do their jobs. Matthew Gentry, chair of biochemistry and molecular biology at the University of Florida and a co-author on the study, described it this way: “Proteins are the cell’s molecular machines, and many of them need sugar tags added in just the right way to fold correctly, travel to the right place and do their jobs.” In Alzheimer’s disease, this sugar-tagging system appears to be overactive. “The Alzheimer’s brain is adding too many of these sugar structures, and this seems to contribute to the disease rather than protect against it.”

In people with Alzheimer’s disease, these sugar chains pile up where they don’t belong. The proteins underneath them start to fail, leading to memory loss and cell death. This condition is called hyperglycosylation.

Metabolic disruptions are widely observed in Alzheimer’s disease, yet their involvement in the molecular cause of the condition has remained underexplored. This study positions hyperglycosylation not as a side effect of Alzheimer’s, but as an active driver of it. Integrating spatial metabolomics and glycomics in transgenic mouse models and post-mortem human brain samples, the researchers demonstrated that brain hyperglycosylation is driven by increased glycan biosynthesis – and that genetically reducing the enzymes responsible for making these sugar structures improved cognitive outcomes in Alzheimer’s mice, while oral glucosamine supplementation impaired them.

The Alzheimer’s brain appears to be uniquely susceptible to this metabolic imbalance, which is amplified by exposure to glucosamine, a sugar-related molecule capable of crossing the blood-brain barrier. When glucosamine reaches the brain in a person with normal cognition, the system handles it without apparent harm. When it enters a brain already producing too many sugar attachments on its proteins, it fuels the very process that is damaging those proteins.

Mechanistically, glucosamine may worsen Alzheimer’s pathology by enhancing protein glycosylation, a metabolic process found to be overactive in Alzheimer’s brains and linked to worsened memory deficits in mouse models.

A Contradiction with Earlier Research

Earlier studies linked glucosamine supplements to a lower dementia risk in cognitively healthy adults. The new findings do not contradict those reports but qualify them. While glucosamine appears safe and potentially protective for a healthy brain, it may be harmful for a brain already experiencing cognitive decline.

A 2022 prospective cohort study published in PubMed Central involving nearly 496,000 participants from the UK Biobank followed over 11 years found that habitual glucosamine use was associated with a modestly lower risk of dementia overall. Healthy mice given the same supplement showed no effect in the animal model experiments either – the harm emerged specifically in subjects already in neurological decline. This suggests glucosamine’s relationship with the brain is conditional: the state of the brain at the time of supplementation may be the deciding factor.

The University of Florida team’s data draws a specific population into focus. About 7.2 million Americans ages 65 and older live with Alzheimer’s disease, and the overlap between that group and regular glucosamine users is substantial, since joint pain is common in older adults and glucosamine is routinely recommended for it. Many people taking this supplement for their knees may also be in the early stages of cognitive decline – sometimes before a formal diagnosis has been made.

The Scale of the Dataset and What It Can Show

To investigate whether glucosamine use influences clinical outcomes in Alzheimer’s disease, the researchers analyzed clinical records from the University of Florida Health system, identifying over 50,000 patients diagnosed with Alzheimer’s disease-related dementias. The AI-assisted review of 12 years of records gave the team statistical power that smaller studies can’t achieve.

Since the study was based on patient records rather than a controlled experiment in people, it cannot show that glucosamine causes faster cognitive decline – only that there’s an association. Answering the causation question would require a study that randomly administers glucosamine to some patients and not to others. If glucosamine may increase the risk of dementia, giving patients the supplement for a trial would raise ethical concerns. One way to test whether glucosamine directly causes cognitive decline would be a clinical trial on patients who took it and then discontinued.

Ramon Sun, senior author and director of the UF Center for Advanced Spatial Biomolecule Research, noted: “Our results suggest that altered metabolism is a significant contributor to Alzheimer’s progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer’s plaques and tangles.”

For decades, Alzheimer’s research was dominated by the amyloid hypothesis – the idea that sticky plaques made of amyloid-beta protein were the primary cause of the disease. The University of Florida findings reframe metabolic dysregulation as an active driver of neurodegeneration rather than a passive symptom, and point to N-glycosylation pathways as a potential target that complements existing strategies focused on amyloid-beta plaques and tau tangles.

Read More: 3 Everyday Beverages With Links to Alzheimer’s Disease

What to Do With This Information

The University of Florida team plans to screen compounds that block the N-glycan molecule and reduce sugar buildup on brain cells to see whether this might slow or even reverse Alzheimer’s progression. The researchers also intend to explore whether other supplements the body processes similarly to glucosamine carry comparable risks for brains in cognitive decline.

Glucosamine is a natural compound found in cartilage – the tough tissue that cushions joints. In supplement form, it is harvested from shells of shellfish or made in a lab. People use glucosamine sulfate orally to treat a painful condition caused by the inflammation, breakdown, and eventual loss of cartilage known as osteoarthritis. For that purpose, the evidence supporting it is already mixed. According to Harvard Health, a 2022 analysis of eight studies involving nearly 4,000 people with knee osteoarthritis found no convincing evidence that glucosamine and chondroitin provided major benefit for the condition.

For people with no cognitive concerns, the current evidence does not give a clear reason to stop taking glucosamine. For anyone who has been diagnosed with MCI or any form of Alzheimer’s disease-related dementia, the University of Florida data adds a direct and specific reason to bring current supplement use up at the next medical appointment. Ask your doctor specifically whether glucosamine is still appropriate given your cognitive health status. The researchers themselves describe the findings as preliminary and in need of validation through a human clinical trial – but the biological mechanism they’ve identified, backed by patient records, human brain imaging, and mouse model data, is detailed enough to warrant that conversation now.

Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.

AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.